737462216/11/202020/04/2021DraftDraft05/02/202125/03/2025David Smadjahttp://admin-epid-prod2.inserm.fr/en/layout/set/print/content/view/full/90448http://admin-epid-prod2.inserm.fr/en/layout/set/print/content/view/full/90761http://admin-epid-prod2.inserm.fr/en/layout/set/print/ccontent/xml/(NodeId)/90448Evaluation de la COagulopathie et de la dysfonction enDOthéliale comme facteur prédictif de la gravité de l'infection par SARS-CoV-2 /COVID19Evaluation of coagulopathy and endothelial dysfunction as a predictive factor for the severity of SARS-CoV-2/COVID-19 infectionSARCODOSARCODOCPP2020-04-048bCPP2020-04-048bBiologieHématologieMaladies infectieusesBiologyHematologyInfectious diseasesOuiYesendotheliumfacteur willebrandCOVID-19hémostasevon Willebrand factorendotheliumCOVID-19haemostasisSMADJADavidHEGP, Service d'hématologie, 20 rue Leblanc, 75015 Paris+33613838972david.smadja@aphp.frUniversité Paris Cité, Inserm, Paris Cardiovascular research center PARCCInsermSMADJADavidHEGP, Service d'hématologie, 20 rue Leblanc, 75015 Paris33613838972david.smadja@aphp.frUMR-S1140 and Biosurgical Research Laboratory (Carpentier Foundation)InsermOuiYesEU response - DiscoveryPubliquePublicANR SARCODO (Fondation de France)ANR SARCODO (France Foundation)AP-HPPublicAP-HPPublicNonNoyannick.vacher@aphp.fryannick.vacher@aphp.frAutresOthersBase de données clinique et biologiqueClinical and laboratory databaseNonNoEtudier la coagulopathie, la lésion vasculaire et les marqueurs de souffrance tissulaire pour caractériser l`aggravation des patients atteints du COVID-19 et permettre l'identification des populations de malades qui vont développer ou aggraver un processus thromboembolique ou microvasculaire mais également nécessiter une anticoagulation curative.Study the coagulopathy, vascular lesion and markers for tissue distress to characterise the exacerbation of patients with COVID-19 and identify patient populations who will develop or experience exacerbation of a thromboembolic or microvascular process, but also require curative anticoagulation.Patients âgés d’au moins 18 ans Hospitalisés pour suspicion de COVID-19 en service de médecine ou de réanimation. Patients bénéficiaires d’un régime de sécurité sociale (hors AME) Patient ayant été informé de l’étude et ayant donné son consentement éclairé par écrit ou pour lequel un proche / personne de confiance a donné son accordPatients aged at least 18 years Hospitalised in an intensive care or medicine department for suspected COVID-19. Patients covered by a social security regime (other than the state welfare scheme) Patient having been informed of the study and having given their informed consent in writing, or for whom a family member/trusted person has given their agreementAdolescence (13 à 18 ans)Adulte (19 à 24 ans)Adulte (25 à 44 ans)Adulte (45 à 64 ans)Personnes âgées (65 à 79 ans)Grand âge (80 ans et plus)Adolescence (13 to 18 years)Adulthood (19 to 24 years)Adulthood (25 to 44 years)Adulthood (45 to 64 years)Elderly (65 to 79 years)Great age (80 years and more)Population généraleGeneral populationMasculinFémininMaleWomanRégionalRegionalÎle-de-FranceÎle-de-FranceHEGP et Hopital CochinHEGP and Cochin Hospital20202020[1000-10 000[ individus[1000-10 000[ individuals10001000Données cliniquesDonnées biologiquesClinical dataBiological dataDossier cliniqueExamen médicalDirect physical measuresMedical registrationOuiYesSang totalPlasmaCellules sanguines isoléesADNWhole bloodPlasmaBlood cells isolatedDNAhttp://admin-epid-prod2.inserm.fr/en/layout/set/print/content/download/100888/3908188/version/1/file/2020- Debuc et al- SCRR Covid19.pdfhttp://admin-epid-prod2.inserm.fr/en/layout/set/print/content/download/100889/3908193/version/1/file/2020- Smadja_Article_Angiopoietin-Covid19-Angiogenesis.pdfhttp://admin-epid-prod2.inserm.fr/en/layout/set/print/content/download/100890/3908198/version/1/file/2020- diehl et al- AIC-covid19.pdfhttp://admin-epid-prod2.inserm.fr/en/layout/set/print/content/download/100891/3908203/version/1/file/2020- Khider et al-CEC JTH.pdfhttp://admin-epid-prod2.inserm.fr/en/layout/set/print/content/download/100892/3908208/version/1/file/2020- Petrazzuolo et al- Oncoimmunology COVID FRP.pdfhttp://admin-epid-prod2.inserm.fr/en/layout/set/print/content/download/100893/3908213/version/1/file/2020- bastard et al- Science AutomAb IFN Covid.pdfhttp://admin-epid-prod2.inserm.fr/en/layout/set/print/content/download/100894/3908218/version/1/file/2021- Philippe_et_al-Angiogenesis-WILLEBRAND.pdfhttp://admin-epid-prod2.inserm.fr/en/layout/set/print/content/download/100895/3908223/version/1/file/2021- Planquette et al- TR- EP Covid.pdfhttp://admin-epid-prod2.inserm.fr/en/layout/set/print/content/download/100896/3908228/version/1/file/2020- Guerin et al- SCRR- Article_MultidimensionalProteomicAppro.pdfhttp://admin-epid-prod2.inserm.fr/en/layout/set/print/content/download/100897/3908233/version/1/file/2020- Goudot et al- tropo covid-Front Med.pdfhttp://admin-epid-prod2.inserm.fr/en/layout/set/print/content/download/106711/4014103/version/1/file/2025- Gendron et al- RPTH-antiPF4H.pdfRelevance of anti–platelet factor 4/heparin antibodies and platelet activation in systemic inflammatory diseases and thrombosis disorders: insight from the COVID-19 pandemichttp://admin-epid-prod2.inserm.fr/en/layout/set/print/content/download/106714/4014119/version/1/file/2024- Smadja- Angiogenesis Letter LongCovid.pdfCirculating endothelial cells: a key biomarker of persistent fatigue after hospitalization for COVID-19http://admin-epid-prod2.inserm.fr/en/layout/set/print/content/download/106715/4014124/version/1/file/2024- SORET et al. CD143 Covid.pdfThe Onset of Intussusceptive Angiogenesis in COVID-19 Patients Might Come from the Mobilization of Stem Cell Sub-Populations Expressing the Hemangioblast Marker CD143http://admin-epid-prod2.inserm.fr/en/layout/set/print/content/download/106716/4014129/version/1/file/2024- Smadja DM_VWF COVID-19 waves_angiogenesis_2024.pdfCirculating Von Willebrand factor: a consistent biomarker predicting in-hospital mortality across different waves of the COVID-19 pandemichttp://admin-epid-prod2.inserm.fr/en/layout/set/print/content/download/106717/4014134/version/1/file/2023- Smadja et al-CD147 SCRR.pdfCD147 Plasma Levels in Hospitalised Patients with Covid-19 Pneumonia Predict Illness Severity and In-Hospital Mortalityhttp://admin-epid-prod2.inserm.fr/en/layout/set/print/content/download/106718/4014139/version/1/file/2023- Philippe et al- Covid long- Angiogenesis.pdfVEGF-A plasma levels are associated with impaired DLCO and radiological sequelae in long COVID patientshttp://admin-epid-prod2.inserm.fr/en/layout/set/print/content/download/100888/3908188/version/1/file/2020- Debuc et al- SCRR Covid19.pdfhttp://admin-epid-prod2.inserm.fr/en/layout/set/print/content/download/100889/3908193/version/1/file/2020- Smadja_Article_Angiopoietin-Covid19-Angiogenesis.pdfhttp://admin-epid-prod2.inserm.fr/en/layout/set/print/content/download/100890/3908198/version/1/file/2020- diehl et al- AIC-covid19.pdfhttp://admin-epid-prod2.inserm.fr/en/layout/set/print/content/download/100891/3908203/version/1/file/2020- Khider et al-CEC JTH.pdfhttp://admin-epid-prod2.inserm.fr/en/layout/set/print/content/download/100892/3908208/version/1/file/2020- Petrazzuolo et al- Oncoimmunology COVID FRP.pdfhttp://admin-epid-prod2.inserm.fr/en/layout/set/print/content/download/100893/3908213/version/1/file/2020- bastard et al- Science AutomAb IFN Covid.pdfhttp://admin-epid-prod2.inserm.fr/en/layout/set/print/content/download/100894/3908218/version/1/file/2021- Philippe_et_al-Angiogenesis-WILLEBRAND.pdfhttp://admin-epid-prod2.inserm.fr/en/layout/set/print/content/download/100895/3908223/version/1/file/2021- Planquette et al- TR- EP Covid.pdfhttp://admin-epid-prod2.inserm.fr/en/layout/set/print/content/download/100896/3908228/version/1/file/2020- Guerin et al- SCRR- Article_MultidimensionalProteomicAppro.pdfhttp://admin-epid-prod2.inserm.fr/en/layout/set/print/content/download/100897/3908233/version/1/file/2020- Goudot et al- tropo covid-Front Med.pdf